In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals (XERS), with a price target of $14.00. The company’s shares closed last Thursday at $3.86.
According to TipRanks.com, Yang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.4% and a 31.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Magenta Therapeutics, and Sarepta Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xeris Pharmaceuticals with a $10.67 average price target, implying a 162.2% upside from current levels. In a report issued on April 6, RBC Capital also maintained a Buy rating on the stock with a $11.00 price target.
See today’s analyst top recommended stocks >>
Xeris Pharmaceuticals’ market cap is currently $256M and has a P/E ratio of -1.80. The company has a Price to Book ratio of 7.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
Read More on XERS:
